[1] 胡兰, 喻雕, 周泽平, 等. 难治性原发免疫性血小板减少症的治疗进展[J]. 实用医学杂志, 2017, 33(3): 337. doi: 10.3969/j.issn.1006-5725.2017.03.001
[2] TRIPATHI AK, SHUKLA A, MISHRA S, et al. Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients[J]. Int J Hematol, 2014, 99(4): 413. doi: 10.1007/s12185-014-1533-y
[3] SUTHERLAND JM, MCLAUGHLIN EA, HIME GR, et al. The Musashi family of RNA binding proteins: master regulators of multiple stem cell populations[J]. Adv Exp Med Biol, 2013, 786: 233.
[4] TAKAHASHI T, SUZUKI H, IMAI T, et al. Musashi-1 post-transcriptionally enhances phosphotyrosine-binding domain-containing m-Numb protein expression in regenerating gastric mucosa[J]. PLoS One, 2013, 8(1): e53540. doi: 10.1371/journal.pone.0053540
[5] BAO W, BUSSEL JB, HECK S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents[J]. Blood, 2010, 116(22): 4639. doi: 10.1182/blood-2010-04-281717
[6] 中华医学会血液学分会止血与血栓学组. 成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J]. 中华血液学杂志, 2016, 37(2): 89.
[7] WÖRMANN B. Clinical indications for thrombopoietin and thrombopoietin-receptor agonists[J]. Transfus Med Hemother, 2013, 40(5): 319.
[8] BUSSEL JB, LAKKARAJA M. Thrombopoietic agents: there is still much to learn[J]. Presse Med, 2014, 43(4 Pt 2): e69.
[9] PELLERIN L, JENKS JA, BEGIN P, et al. Regulatory T cells and their roles in immune dysregulation and allergy[J]. Immunol Res, 2014, 58(2/3): 358.
[10] NISHIMOTO T, KUWANA M. CD4+CD25+Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia[J]. Semin Hematol, 2013, 50(Suppl 1): S43.
[11] ZHANG JK, ZHANG QY, LI YW, et al. Immune dysregulation in primary immune thrombocytopenia patients[J]. Hematology, 2018, 23(8): 510. doi: 10.1080/10245332.2018.1435021
[12] 杨媛媛, 张凤琦, 潘誉, 等. 原发免疫性血小板减少症患者脾脏组织调节性T细胞和Th17细胞数量的研究[J]. 中华血液学杂志, 2017, 38(3): 227.
[13] ZHU YD, ZHU H, XIE XB, et al. MicroRNA expression profile in Treg cells in the course of primary immune thrombocytopenia[J]. J Investig Med, 2019, 67(8): 1118. doi: 10.1136/jim-2019-001020
[14] ARANDI N, MIRSHAFIEY A, JEDDI-TEHRANI M, et al. Alteration in frequency and function of CD4+CD25+FOXP3+regulatory T cells in patients with immune thrombocytopenic purpura[J]. Iran J Allergy Asthma Immunol, 2014, 13(2): 85.
[15] 王琦, 计雪强, 邵惠江, 等. 免疫性血小板减少症(ITP)患儿外周血调节性T细胞数量减少伴随自噬的降低[J]. 细胞与分子免疫学杂志, 2018, 34(9): 834.
[16] 姜明敏, 李玉婷, 王丽娟, 等. 血小板生成素对免疫性血小板减少小鼠脾脏T淋巴细胞亚群的影响[J]. 免疫学杂志, 2019, 35(8): 671.
[17] LIU Y, WANG R, HAN P, et al. Effect of recombinant human thrombopoietin on immune thrombocytopenia in pregnancy in a murine model[J]. Int Immunopharmacol, 2019, 67(2): 287.
[18] KONG ZY, QIN P, XIAO S, et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy[J]. Blood, 2017, 130(9): 1097. doi: 10.1182/blood-2017-01-761262
[19] 陶媛, 吴秉毅, 杜庆锋, 等. 重组人血小板生成素可能通过调节免疫负调控因子水平治疗免疫性血小板减少性紫癜[J]. 血栓与止血学, 2014, 20(6): 315. doi: 10.3969/j.issn.1009-6213.2014.06.013
[20] 罗洪强, 封蔚莹, 钟永根, 等. CBA技术检测ITP患者Th1/Th2细胞因子平衡偏移的临床意义[J]. 中国实验血液学杂志, 2016, 24(6): 1846.
[21] 王明镜, 许勇钢, 丁晓庆, 等. 免疫性血小板减少症患者Th1/Th2细胞失衡与特异性转录因子表达异常[J]. 临床血液学杂志, 2018, 31(5): 379.
[22] LYU MG, LI Y, HAO YT, et al. Elevated Semaphorin 5A correlated with Th1 polarization in patients with chronic immune thrombocytopenia[J]. Thromb Res, 2015, 136(5): 859.
[23] 瞿文, 伍星, 王珺, 等. 免疫性血小板减少性紫癜患者的T细胞免疫状态[J]. 天津医药, 2012, 40(4): 389. doi: 10.3969/j.issn.0253-9896.2012.04.028
[24] BART-SMITH EE, KORDASTI S, KULASEKARARAJ AG, et al. Successful treatment of aplastic anaemia associated with HIV infection with eltrombopag: implications for a possible immunomodulatory role[J]. AIDS, 2014, 28(18): 2786. doi: 10.1097/QAD.0000000000000504
[25] ZAIMOKU Y, PATEL BA, KAJIGAYA S, et al. Deficit of circulating CD19+CD24hiCD38hi regulatory B cells in severe aplastic anaemia[J]. Br J Haematol, 2020, 190(4): 610. doi: 10.1111/bjh.16651
[26] 罗洪强, 钟永根, 封蔚莹. rhTPO对原发性免疫性血小板减少性紫癜患者T、B淋巴细胞免疫功能的影响[J]. 中国实验血液学杂志, 2019, 27(6): 1962.